Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocortisone Probutate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 2/20 | 0.82 |
| ▸ | PGR | P06401 | 4/20 | 0.82 |
| ▸ | AR | P10275 | 3/20 | 0.82 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.82 |
| ▸ | NR3C2 | P08235 | 7/20 | 0.82 |
| ▸ | HIF1A | Q16665 | 8/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocortisone Probutate SCHEMBL30507561 | 1.00 | PGR (0.82) | PGRARCHRM1NR3C2NR3C1 | |
| Hydrocortisone Probutate SCHEMBL4280673 | 1.00 | PGR (0.82) | PGRARCHRM1NR3C2NR3C1 | |
| Hydrocortisone Probutate SCHEMBL4290122 | 1.00 | PGR (0.82) | PGRARCHRM1NR3C2NR3C1 | |
| Hydrocortisone Probutate SCHEMBL14339602 | 1.00 | PGR (0.82) | PGRARCHRM1NR3C2NR3C1 | |
| SCHEMBL122187 | 0.97 | PGR (0.85) | PGRARCHRM1NR3C2NR3C1 | |
| SCHEMBL4290159 | 0.97 | PGR (0.85) | PGRARCHRM1NR3C2NR3C1 | |
| SCHEMBL605474 | 0.97 | NR3C2 (0.85) | PGRARCHRM1NR3C2NR3C1 | |
| SCHEMBL4278627 | 0.95 | PGR (0.91) | PGRARCHRM1NR3C2NR3C1 | |
| SCHEMBL10858602 | 0.94 | PGR (0.81) | PGRARCHRM1NR3C2NR3C1 | |
| SCHEMBL10535271 | 0.94 | NR3C2 (0.80) | PGRARCHRM1NR3C2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2335 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250255781-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-14 | — | — | US | claimed |
| US-12296043-B2 | Liquisoft capsules | PATHEON SOFTGELS INC. (US) | 2025-05-13 | — | — | US | claimed |
| EP-4510999-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | Bristol-Myers Squibb Company (US) | 2025-02-26 | — | — | EP | claimed |
| US-20250017846-A1 | TOPICAL ANALGESICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-01-16 | — | — | US | claimed |
| EP-4475851-A1 | FORMULATIONS FOR TRANSDERMAL ADMINISTRATION OF ACTIVE AGENTS | Dyve Biosciences, Inc. (US) | 2024-12-18 | — | — | EP | claimed |
| US-20240390265-A1 | FORMULATIONS FOR TRANSDERMAL ADMINISTRATION OF ACTIVE AGENTS | DYVE BIOSCIENCES, INC. | 2024-11-28 | — | — | US | claimed |
| EP-4433091-A1 | PROCESS AND THERAPEUTIC COMPOSITION FOR TREATING AND PREVENTING SEVERE INJECTION SITE REACTIONS | Brii Biosciences, Inc. (US) | 2024-09-25 | — | — | EP | claimed |
| US-20240165020-A1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2024-05-23 | — | — | US | claimed |
| EP-4360653-A2 | LIQUISOFT CAPSULES | Patheon Softgels Inc. (US) | 2024-05-01 | — | — | EP | claimed |
| CN-117752989-A | Racket comprising a socket and a plug | 斯帝卡体育用品有限公司 | 2024-03-26 | — | — | CN | claimed |
| EP-1698336-A1 | Antifungal compositions comprising Sertaconazole and either Hydrocortisone or an antibacterial agent | FERRER INTERNACIONAL, S.A. (ES) | 2006-09-06 | — | — | EP | claimed |
| US-20060162722-A1 | Therapeutic aerosol device | PARI GMBH SPEZIALISTEN FUR EFFEKTIVE INHALATION (DE) | 2006-07-27 | — | — | US | claimed |
| EP-1534370-A1 | THERAPEUTIC AEROSOL DEVICE | PARI GmbH Spezialisten für effektive Inhalation (DE) | 2005-06-01 | — | — | EP | claimed |
| WO-2004020029-A1 | THERAPEUTIC AEROSOL DEVICE | Pari GmbH Spezialisten für effektive Inhalation (DE) | 2004-03-11 | — | — | WO | claimed |
| WO-1997015298-A1 | COMBINATION OF LTD, RECEPTOR ANTAGONISTS WITH GLUCOCORTICOSTEROIDS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-05-01 | — | — | WO | claimed |
| EP-0484529-B1 | SKIN CREAM PREPARATION FOR EXTERNAL USE | HISAMITSU PHARMACEUTICAL CO (JP) | 1994-04-27 | — | — | EP | claimed |
| US-4902682-A | W/O cream containing hydrocortisone diester | BEIERSDORF AG (DE) | 1990-02-20 | — | — | US | claimed |
| EP-0217146-A2 | W/O creams containing hydrocortisone diesters | Beiersdorf Aktiengesellschaft (DE) | 1987-04-08 | — | — | EP | claimed |
| EP-0217141-A2 | W/O creams containing 17-propionate-21-acetate | Beiersdorf Aktiengesellschaft (DE) | 1987-04-08 | — | — | EP | claimed |
| US-4290962-A | HYDROCORTISONE 17-BUTYRATE-21-PROPIONATE, USEFUL AS AN ANTIINFLAMMATORY AGENT | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1981-09-22 | — | — | US | claimed |